The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Tafasitamab with lenalidomide in patients with relapsed central nervous system lymphoma
James Rubenstein, MD, PhD, University of California San Francisco, San Francisco, CA, discusses the interim analysis of a Phase I/II study (NCT05351593) evaluating tafasitamab in combination with lenalidomide for patients with highly refractory primary and secondary central nervous system (CNS) lymphoma. He highlights encouraging response rates and durable remissions with manageable toxicity, supporting further development of this CD19-targeted approach. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
